Royce & Associates LP lifted its position in Inogen, Inc. (NASDAQ:INGN - Free Report) by 499.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 311,199 shares of the medical technology company's stock after acquiring an additional 259,308 shares during the quarter. Royce & Associates LP owned 1.31% of Inogen worth $2,854,000 as of its most recent SEC filing.
Several other hedge funds also recently made changes to their positions in INGN. AlphaQuest LLC acquired a new position in Inogen during the 4th quarter valued at approximately $43,000. BNP Paribas Financial Markets boosted its position in Inogen by 13.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 42,137 shares of the medical technology company's stock valued at $409,000 after purchasing an additional 5,131 shares during the period. Geode Capital Management LLC boosted its position in Inogen by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company's stock valued at $5,377,000 after purchasing an additional 5,921 shares during the period. Quarry LP acquired a new position in Inogen during the 3rd quarter valued at approximately $59,000. Finally, Ieq Capital LLC acquired a new position in Inogen during the 4th quarter valued at approximately $94,000. Institutional investors and hedge funds own 89.94% of the company's stock.
Inogen Stock Down 1.3 %
Inogen stock traded down $0.10 during mid-day trading on Friday, hitting $7.35. 321,579 shares of the company's stock traded hands, compared to its average volume of 233,771. The firm has a 50 day moving average price of $9.75 and a 200 day moving average price of $9.68. The company has a market cap of $195.00 million, a PE ratio of -3.27 and a beta of 1.15. Inogen, Inc. has a one year low of $6.14 and a one year high of $13.33.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on INGN shares. Needham & Company LLC restated a "hold" rating on shares of Inogen in a research report on Wednesday, February 26th. StockNews.com downgraded Inogen from a "buy" rating to a "hold" rating in a research note on Wednesday, February 26th.
Read Our Latest Stock Analysis on Inogen
Inogen Profile
(
Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Recommended Stories
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
